Survival outcomes for HER2-low breast cancer: Danish national data by Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm

Subjects: Get full text

Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer by Jing-Jing Liu, Jing-Jing Liu, Jing-Jing Liu, Jing-Jing Liu, Yi Zhang, Yi Zhang, Yi Zhang, Yi Zhang, Shi-Chao Zhang, Shi-Chao Zhang, Shi-Chao Zhang, Shi-Chao Zhang, Xu Liu, Xu Liu, Xu Liu, Xu Liu, Shu-Nan Wang, Shu-Nan Wang, Shu-Nan Wang, Shu-Nan Wang, Xin-Yu Liu, Xin-Yu Liu, Xin-Yu Liu, Xin-Yu Liu, Jin Zhang, Jin Zhang, Jin Zhang, Jin Zhang

Subjects: “…HER2-low…”
Get full text

Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff by Agata Wróbel, Michel Vandenberghe, Marietta Scott, Frances Jones, Tsuyoshi Matsuo, Anne-Marie Boothman, Jessica Whiteley, Craig Barker

Subjects: Get full text

Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China by Hong Lv, Junqiu Yue, Qingfu Zhang, Fangping Xu, Peng Gao, Haifeng Yang, Xiu Nie, Lingfei Kong, Guanjun Zhang, Jianming Li, Shiwei Xiao, Hongmei Wu, Aiyan Xing, Min Hong, Jun Fan, Huijuan Guan, Peilong Cao, Hengli Ni, Wentao Yang

Subjects: Get full text

Fully automatic HER2 tissue segmentation for interpretable HER2 scoring by Mathias Öttl, Jana Steenpass, Frauke Wilm, Jingna Qiu, Matthias Rübner, Corinna Lang-Schwarz, Cecilia Taverna, Francesca Tava, Arndt Hartmann, Hanna Huebner, Matthias W. Beckmann, Peter A. Fasching, Andreas Maier, Ramona Erber, Katharina Breininger

Subjects: “…HER2…”
Get full text

HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions by Dimitrios Papageorgiou, Galateia Liouta, Ioakeim Sapantzoglou, Eleftherios Zachariou, Dimitra Pliakou, Katerina Papakonstantinou, Theofanis Floros, Evangelia Pliakou

Subjects: Get full text

Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case re... by Javier Muñoz, Sabrina Nucera, Nuria Rubira Garcia, Isaac Cebrecos, Gabriela Oses, Sergi Ganau, Esther Sanfeliu, Pedro Jares, Mercedes Marín-Aguilera, Patricia Galván, Fara Brasó-Maristany, Olga Martínez-Sáez, Enric Cascos, Carme Font, Francesco Schettini

Subjects: Get full text

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer by Yisun Jeong, Hyungjoo Kim, Daeun You, Soo Youn Cho, Sun Young Yoon, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee, Sangmin Kim

Subjects: “…HER2…”
Get full text

Cáncer de mama HER2-bajo: una nueva era en terapias dirigidas by Benjamín Walbaum, MD, Francisco Acevedo, MD, MSc, Lidia Medina, RN, César Sánchez, MD

Subjects: Get full text

Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study by Fangchao Zheng, Feng Du, Zixuan Yang, Xue Wang, Jian Yue, Yun Ling, Peng Yuan

Subjects: Get full text

Advances in research and current challenges in the treatment of advanced HER2-low breast cancer by Qiang Qin

Subjects: Get full text

HER2-low breast cancer. Diagnostics, treatment and its adverse events by Hanna Bartkowiak, Damian Grubski, Kacper Ziarnik, Filip Nadolny, Jędrzej Jabłoński, Martyna Kania, Agnieszka Adamowska, Alicja Śniatała

Subjects: Get full text

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy by Yan Zhang, Wenxuan Fan, Fei Su, Xiaoling Zhang, Yunyi Du, Weiling Li, Yangjun Gao, Wenqing Hu, Jun Zhao

Subjects: “…HER2-positive…”
Get full text

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB by Martina Kurnia Rohmah

Subjects: Get full text

HER2-Low Breast Cancer—Current Knowledge and Future Directions by Abeer M. Shaaban, Tanvier Kaur, Elena Provenzano

Subjects: “…HER2-low…”
Get full text

Progress of Research on Advanced Non-Small Cell Lung Cancer with HER-2 Mutation by Liang ZHANG, Changliang YANG, Peidong LI, Ying CHENG

Subjects: Get full text

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors by Fatemah S. Albalawi, Mashooq A. Bhat, Ahmed H. Bakheit, A. F. M. Motiur Rahman, Nawaf A. Alsaif, Alan M. Jones, Isolda Romero-Canelon

Subjects: Get full text

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

Subjects: Get full text

Clinical characteristics and therapeutic direction of HER2 low-expression breast cancer by Linlin Zhou, Yinghui Zhang, Jiayu Zhang, Hongyu Wang, Bozhi Zhao, Yixin Cai, Yuansong Qu, Xinxin Li, Dongwei Zhang

Subjects: Get full text

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases by T.  Yu.  Semiglazova, S.  M.  Sharashenidze, S.  N.  Kerimova, V.   V. Klimenko, A. Yu.  Malygin, G.  A.  Dashyan, R.   M. Paltuev, V.  V.  Semiglazov, P.   V. Krivorotko, S.  N.  Novikov, V.   F. Semiglazov

Subjects: “…her2-positive breast cancer…”
Get full text